SYSTEM PROBLEMS:
We are currently experiencing technical problems with content and functionality requiring a login.
We apologize for the inconvience.
- Sort by:
|
<< first | < prev
page:
of 2
|
records per page:
next >
| last >>
|
| pages: 1 2
|
presentations:
1 to
50 of
100
|
Preventing Pediatric HIV and Managing HIV-Infected Children: Where Are We Now, and Where Are We Going?
Diana M. Gibb
University College London, London, United Kingdom
Directing Chronic Virus Infection Through Viral Regulation of Innate Immune Defenses
Michael Gale
University of Washington, Center for Innate Immunity and Immune Disease, Seattle, WA, United States
Special Presentation: PEPFAR 3.0: Controlling the Epidemic and Delivering on the Promise of an AIDS-Free Generation
Ambassador Deborah L. Birx, MD
US Department of State, Washington, DC, United States
Joint Estimation of HIV Progression and Survival: A Pooled Analysis of 25 Countries
Tara D. Mangal
Imperial College London, London, United Kingdom
Impact of Emergency Department HIV Testing and Linkage to Care: 25 Years' Experience
Thomas C. Quinn
National Institute of Allergy and Infectious Diseases (NIAID), Baltimore, MD, United States
Linkage to Care and Viral Suppression Among New HIV Diagnoses, New York City, 2006-13
Lucia V. Torian
New York City Department of Health and Mental Hygiene, Long Island City, NY, United States
Care and Viral Suppression Among Women, 18 US Jurisdictions
Ndidi Ike
US Centers for Disease Control and Prevention (CDC), Atlanta, GA, United States
Time Above 1500 Copies/ml: A Viral-Load Measure for Assessing Transmission Risk of HIV-Positive Patients in Care
Lytt I. Gardner
Centers for Disease Control and Prevention, Atlanta, GA, United States
Incidence and Risk Factors for Sexual Assault Among MSM and Young Women in Coastal Kenya
Adrian D. Smith
Nuffield Department of Population Health, Oxford, United Kingdom
Impact of the Ebola Epidemic on HIV Care in Macenta, Forest Guinea, 2014
David Leuenberger
Mission Philafricaine, Conakry, Guinea
Favipiravir in Patients with Ebola Virus Disease: Early Results of the JIKI trial in Guinea
Denis Malvy
Université de Bordeaux, Bordeaux, France
Scientific Overview: The Clinical Pharmacology of HIV Prevention
Marta Boffito
Chelsea and Westminster Hospital, NHS Foundation Trust/Imperial College, London, United Kingdom
Intracellular Pharmacokinetics of Sofosbuvir In Vivo
Joseph Rower
University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, United States
Drug-Drug Interactions Between Anti-HCV Regimen Ledipasvir/Sofosbuvir and Antiretrovirals
Polina German
Gilead Sciences, Inc., Foster City, CA, United States
Emtricitabine-Triphosphate in Dried Blood Spots (DBS) as a Marker of Recent Dosing
Jose R. Castillo-Mancilla
University of Colorado-AMC, Aurora, CO, United States
Impact of EFV PK/PG on Neuropsychological Performance in Older HIV+ Patients
Uriel S. Sandkovsky
University of Nebraska Medical Center, Omaha, NE, United States
Levonorgestrel Implant + EFV-Based ART: Unintended Pregnancies and Associated PK Data
Kimberly K. Scarsi
University of Nebraska Medical Center, Omaha, NE, United States
A Phase IV PrEP Study Reveals Limited Ex Vivo Potency of Oral Maraviroc Against HIV-1
Julie Fox
Guys and St Thomas' NHS Foundation Trust, London, United Kingdom
Pomalidomide for Kaposi Sarcoma in People With and Without HIV: A Phase I/II Study
Mark N. Polizzotto
National Cancer Institute (NCI), Bethesda, MD, United States
Prognostic Model for Patients With Kaposi Sarcoma Treated With ART Alone in Africa
Jeffrey Martin
University of California San Francisco, San Francisco, CA, United States
One-Year Follow-up of HIV+ Women Screened With VIA, Cytology and HPV in South Africa
Cynthia Firnhaber
University of Witswatersrand, Johannesburg, South Africa
High Rate of HSIL on HRA in HIV+ Women Not Meeting Criteria for Anal Cancer Screening
Fanny Ita-Nagy
Icahn School of Medicine at Mount Sinai, New York, NY, United States
Xpert MTB/RIF Ultra: A New Near-Patient TB Test With Sensitivity Equal to Culture
David Alland
Rutgers New Jersey Medical School, Newark, NJ, United States
Majority of XDR TB Cases Are Due to Transmission in a High-HIV-Prevalence Setting
N. Sarita Shah
US Centers for Disease Control and Prevention, Atlanta, GA, United States
Linkage to HIV/TB Care in South Africa: A Randomized Trial of Health Navigators
Ingrid V. Bassett
Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States
Is It Safe to Stop Cotrimoxazole in Adults on ART: COSTOP, a Noninferiority RCT
Jonathan B. Levin
MRC/UVRI Uganda Research Unit on AIDS, Entebbe, Uganda
High-Dose Rifampin, SQ109 and Moxifloxacin for Treating TB: The PanACEA MAMS-TB Trial
Martin J. Boeree
Radboudumc, Nijmegen, Netherlands
Durable Control of Viral Rebound in Humanized Mice by ABX464 Targeting Rev Functions
Jamal Tazi
University of Montpellier, Montpellier, France
Residual Viremia Caused by Clonally Expanded Tumor-Infiltrating CD4+ Cells
Francesco R. Simonetti
National Cancer Institute (NCI), Frederick, MD, United States
Analysis of HIV RNA in Single Cells Reveals Clonal Expansions and Defective Genomes
Mary F. Kearney
National Cancer Institute, Frederick, MD, MD
Low-Level HIV Viremias Originate in Part From Infected Proliferating Cells
Marta E. Bull
University of Washington, Seattle, WA, United States
Treatment With a TLR7 Agonist Induces Transient Viremia in SIV-Infected ART-Suppressed Monkeys
James B. Whitney
Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States
Panobinostat Broadly Activates Latent HIV-1 Proviruses in Patients
Sarah E. Palmer
Westmead Millennium Institute and University of Sydney, Westmead, Australia
The Size of the Active HIV Reservoir Predicts Timing of Viral Rebound
Jonathan Li
Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA, United States
Biomarkers to Predict Viral Rebound at Antiretroviral Therapy Interruption in SPARTAC
John Frater
University of Oxford, Oxford, United Kingdom
HIV-1 Diversity and Tropism of Rebound Virus After Treatment Discontinuation
Maria M. Bednar
University of North Carolina, Durham, NC, United States
Discussion Leader
Eric A. Engels
National Cancer Institute, Bethesda, MD, United States
Cancer in HIV-Infected Children: Record Linkage Study in South Africa
Matthias Egger
University of Bern, Bern, Switzerland
High Cancer Risk Among the HIV-Infected Elderly in the United States
Elizabeth L. Yanik
National Cancer Institute (NCI), Rockville, MD, United States
Smoking Outweighs HIV-Related Risk Factors for Non–AIDS-Defining Cancers
Keri N. Althoff
Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States
High Frequency of Early Lung Cancer Diagnosis With Chest CT in HIV-Infected Smokers
Alain Makinson
University Hospital Montpellier, UMI233, Montpellier, France
CD4 Measures as Predictors of Lung Cancer Risk and Prognosis in HIV Infection
Keith Sigel
Icahn School of Medicine at Mount Sinai, New York, NY, United States
Discussion Leader
Judith A. Aberg
Icahn School of Medicine at Mount Sinai, New York, NY, United States
Local and Systemic Humoral Responses to Cryptococcal Meningitis in Patients With AIDS
Erin E. Finn
Mucosal and Vaccine Research Colorado, Aurora, CO, United States
Antiretroviral Therapy Alters the CSF Immune Response in Cryptococcal Meningitis
James E. Scriven
Liverpool School of Tropical Medicine, Liverpool, United Kingdom
Detrimental Outcomes of Unmasking Cryptococcal Meningitis With Recent ART Initiation
Joshua Rhein
University of Minnesota, Minneapolis, MN, United States
Impact of ART on Mortality in Cryptococcal Meningitis Patients: High-Income Settings
Suzanne M. Ingle
University of Bristol, Bristol, United Kingdom
Adjunctive Sertraline for the Treatment of HIV-Associated Cryptococcal Meningitis
Joshua Rhein
University of Minnesota, Minneapolis, MN, United States
|
<< first | < prev
page:
of 2
|
records per page:
next >
| last >>
|
| pages: 1 2
|
presentations:
1 to
50 of
100
|
